This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

In two five-week RCTs, THC:CBD was more effective than placebo when added to existing therapy for the management of neuropathic pain associated with MS and in patients with neuropathic pain stemming from mixed etiologies. In a longer study (12 weeks) in patients with diabetic neuropathy, there was no difference between THC:CBD and placebo in the management of neuropathic pain. This may suggest that THC:CBD is either not effective in diabetic neuropathy or that the analgesic effects of THC:CBD diminished with longer duration of treatment in this population.
Overall, the limited evidence suggests that cannabinoids may provide pain relief in patients with
HIV or MS who have neuropathic pain when used as add on therapy.